Histogen Update - Spencer Kobren Speaks With Dr. Craig L. Ziering
Collapse
X
-
12 or 26 it doesnt matter :-)
I like it how people here who obviously have an agenda try to sound smart but then even dont get the numbers correct :-)
TzzzzzComment
-
I just thought the amount of patients in the trial would have been split in half. If the results are the basically 100% repeatable and they show that in phase 1/2 over an even larger area without any side effects this would be a "cure" for myself and anyone who is just beginning hair loss since it appears to strengthen weaker hairs or hairs that would have eventually begun to die out.
Is that agenda comment directed at me RichardDawkins? Id love to know what it is lol besides this hsc passing the upcoming trials. I will be so excited if they match the preclinical trials numbers.Comment
-
If the results are the basically 100% repeatable and they show that in phase 1/2 over an even larger area without any side effects this would be a "cure" for myself and anyone who is just beginning hair loss since it appears to strengthen weaker hairs or hairs that would have eventually begun to die out.Comment
-
Originally posted by UK_
Why would they do that? 20 of the 24 patients experienced 'statistically significant hair growth at the three efficacy endpoints' - that means those patients experienced similar gains at similar times, which is why Gail stated there is such a high degree that these findings will be repeated especially given that this was merely a safety run, the trial wasnt even aimed at producing evidence of efficacy yet, that is the job of the current trial.
Im so hopeful that this hsc can get through the upcoming trials without any side effects popping up from increased dosages or higher percentage solution of hsc.
I appreciate all the corrections on the subject guys.Comment
-
The pilot study of Histogen's H.S.C. used twenty-four subjects, from which half received placebo and the other half received the experimental compound. All twenty-four subjects are used in analyzing results, but in only the latter twelve can one observe the actual effects of the drug.Comment
-
Why would they do that? 20 of the 24 patients experienced 'statistically significant hair growth at the three efficacy endpoints' - that means those patients experienced similar gains at similar times, which is why Gail stated there is such a high degree that these findings will be repeated especially given that this was merely a safety run, the trial wasnt even aimed at producing evidence of efficacy yet, that is the job of the current trial.
Well that's the basic idea.Comment
-
The pilot study of Histogen's H.S.C. used twenty-four subjects, from which half received placebo and the other half received the experimental compound. All twenty-four subjects are used in analyzing results, but in only the latter twelve can one observe the actual effects of the drug.
I thought all patients received the following:
1.One placebo injection
2.One regular HSC injection
3.One dermabraded area with regular HSC
4.One area with a higher concentration of HSC
A number of those in the control exhibited growth?... ? Your saying a number of those patients who received only a control experienced growth of new hair?Comment
-
Have you a link to the source that confirms this?
I thought all patients received the following:
1.One placebo injection
2.One regular HSC injection
3.One dermabraded area with regular HSC
4.One area with a higher concentration of HSC
A number of those in the control exhibited growth?... ? Your saying a number of those patients who received only a control experienced growth of new hair?
I admit I might be misinterpreting something, here; perhaps Dr. Ziering (or someone else properly affiliated with research on H.S.C.) could shed a bit of light on the matter.Comment
-
Well if that's the case, I wonder what was in the control!! - dihydrogen monoxide probably -the holy grail lol.
I always thought they split the scalp into four different parts and had the control and HSC in different quadrants (I mean, that's how Aderans do it lol), I assumed this when Gail Naughton stated the following:
"There were no adverse reactions seen in any of the treated 24 patients at baseline"
I mean, you dont ever expect to see adverse reactions if someone just takes the sugar pill...Comment
-
That is amazing. Disheartening it is not yet approved in the U.S. which scares me a bit. Im glad histogen is planning on release outside the United states due to how bad of a job the fda does.
Made me smile seeing that kid ending up with no scares on his chest. Glad to see futuristic seeming treatments already being used in hospitals.Comment
-
That is amazing. Disheartening it is not yet approved in the U.S. which scares me a bit. Im glad histogen is planning on release outside the United states due to how bad of a job the fda does.
Made me smile seeing that kid ending up with no scares on his chest. Glad to see futuristic seeming treatments already being used in hospitals.Comment
-
Yes, I am saying a number of patients in the control group experienced growth of new hair. I recall asking Histogen about this, via e-mail, a few months ago, and this seemed to be the answer given (I'll post the conversation, if I can locate it). Also, I draw the notion of two separate subject groups — a control and an experimental — from this graph, presented on the company's Web site: http://www.histogen.com/images/termi...sity_graph.gif (found at, http://www.histogen.com/aboutus/news_events.htm#25, about a third of a way down the page).
I admit I might be misinterpreting something, here; perhaps Dr. Ziering (or someone else properly affiliated with research on H.S.C.) could shed a bit of light on the matter.Comment
Comment